<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Oncol</journal-id><journal-id journal-id-type="publisher-id">CO</journal-id><journal-title-group><journal-title>Current Oncology</journal-title></journal-title-group><issn pub-type="ppub">1198-0052</issn><issn pub-type="epub">1718-7729</issn><publisher><publisher-name>Multimed Inc.</publisher-name><publisher-loc>66 Martin St. Milton, ON, Canada L9T 2R2</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19478899</article-id><article-id pub-id-type="pmc">2687803</article-id><article-id pub-id-type="publisher-id">co16-s1-s33</article-id><article-categories><subj-group subj-group-type="heading"><subject>Urologic Oncology</subject></subj-group></article-categories><title-group><article-title>Inhibition of m<sc>tor</sc> in kidney cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kapoor</surname><given-names>A.</given-names></name><degrees>MD</degrees><xref ref-type="corresp" rid="c1-co16-s1-s33"/></contrib></contrib-group><author-notes><corresp id="c1-co16-s1-s33">Correspondence to: Anil Kapoor, Juravinski Cancer Centre, McMaster University, 699 Concession Street, Hamilton, Ontario L8V 5C2. E-mail:
<email>Kapoor4@mcmaster.ca</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2009</year></pub-date><volume>16</volume><issue>Suppl 1</issue><fpage>S33</fpage><lpage>S39</lpage><permissions><copyright-statement>2009 Multimed Inc.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The mammalian target of rapamycin (m<sc>tor</sc>) has been shown to be an important target mechanism in the treatment of renal cell carcinoma (<sc>rcc</sc>). In first-line treatment for patients with disease having poor prognostic features, temsirolimus, an m<sc>tor</sc> inhibitor approved for treatment of advanced <sc>rcc</sc>, has demonstrated benefit over interferon alfa in both overall and progression-free survival. Everolimus, a second m<sc>tor</sc> inhibitor that has showed activity in <sc>rcc</sc>, led to improved progression-free survival in a comparison with placebo in patients whose <sc>rcc</sc> progressed after treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors (sunitinib, sorafenib, or both). There is now compelling clinical evidence for the effectiveness of targeting m<sc>tor</sc> in the treatment of <sc>rcc</sc>.</p></abstract><kwd-group><kwd>Temsirolimus</kwd><kwd>everolimus</kwd><kwd>sirolimus</kwd><kwd>m<sc>tor</sc> inhibitors</kwd><kwd>renal cell carcinoma</kwd><kwd>kidney cancer</kwd></kwd-group></article-meta></front><body><sec><label>1.</label><title>INTRODUCTION</title><p>Over the last few years, treatment for metastatic renal cell carcinoma (m<sc>rcc</sc>) has undergone a paradigm shift from the mainstay of cytokine therapy (interferon alfa and interleukin-2) to new targeted therapies, including multiple receptor tyrosine kinase (<sc>rtk</sc>) inhibitors and mammalian target of rapamycin (m<sc>tor</sc>) inhibitors. The new <sc>rtk</sc> inhibitors, which include sunitinib (Sutent: Pfizer Canada, Kirkland, QC) and sorafenib (Nexavar: Bayer HealthCare AG, Leverkusen, Germany), interfere with tumour-cell proliferation and angiogenesis. Sunitinib and sorafenib have both shown efficacy in patients with advanced good- to intermediate-prognosis <sc>rcc</sc>. Sunitinib has demonstrated activity as a first-line therapy for m<sc>rcc</sc>
<xref ref-type="bibr" rid="b1-co16-s1-s33">1</xref>, and sorafenib has demonstrated activity in patients with failure of prior cytokine therapy <xref ref-type="bibr" rid="b2-co16-s1-s33">2</xref>. As compared with interferon alfa, the m<sc>tor</sc> inhibitor temsirolimus (CCI-799; Torisel: Wyeth, Madison, NJ, U.S.A.) has been shown to prolong overall survival (<sc>os</sc>) in previously untreated poor-prognosis patients with advanced <sc>rcc</sc>
<xref ref-type="bibr" rid="b3-co16-s1-s33">3</xref>.</p></sec><sec><label>2.</label><title>THE mTOR PATHWAY</title><p>A substantial body of research, including clinical and preclinical studies, has identified a central role for the m<sc>tor</sc> signalling pathway in cell growth, proliferation, survival, and angiogenesis. Aberrations of m<sc>tor</sc>-mediated signalling pathways and m<sc>tor</sc> upregulation have been discovered in many different tumour types, establishing the m<sc>tor</sc> pathway and its inhibition as a promising treatment target in human cancers.</p><p>Multiple stimuli such as growth factors [for example, epidermal growth factor (<sc>egf</sc>), platelet-derived growth factor (<sc>pdgf</sc>), and insulin-like growth factor (<sc>igf</sc>)], nutrients, oxygen, and stress can lead to activation of the m<sc>tor</sc> pathway and downstream signalling.</p><p>The m<sc>tor</sc> kinase, the central regulator of the m<sc>tor</sc> signalling pathway, is a sizeable (289 kDa) polypeptide serine/threonine&#x02013;specific kinase that is part of the phosphoinositide 3 kinase (<sc>pi</sc>3<sc>k</sc>)&#x02013;related kinase family <xref ref-type="bibr" rid="b4-co16-s1-s33">4</xref>. By regulating general protein biosynthesis, m<sc>tor</sc> kinase is involved in the control of a wide variety of growth-related cellular functions such as transcription, translation, membrane trafficking, protein degradation, and reorganization of the actin cytoskeleton <xref ref-type="bibr" rid="b4-co16-s1-s33">4</xref>,<xref ref-type="bibr" rid="b5-co16-s1-s33">5</xref>.</p><sec><label>2.1</label><title>Upstream Activation of mTOR Signalling</title><p>Signalling through the m<sc>tor</sc> pathway starts with the receipt of cell growth and survival signals relayed to the internal cellular environment by <sc>rtk</sc>s on the plasma membrane. Activation of protein kinase B [Akt (a serine/threonine protein kinase)] by <sc>pi</sc>3<sc>k</sc> is the key event in the signalling cascade. It results from an accumulation of phosphatidylinositol (3,4,5)-trisphosphate (<sc>pip</sc>3) formed by <sc>pi</sc>3<sc>k</sc> from phosphatidylinositol 4,5-bisphosphate (<sc>pip</sc>2), which leads to phosphorylation of Akt.</p><p>Once substantially accumulated, the phospholipid <sc>pip</sc>3 serves as a source for recruiting kinases to the plasma membrane, including the Akt family of kinases and pyruvate dehydrogenase kinase 1 (<sc>pdk</sc>1). The <sc>pdk</sc>1 activates Akt, partly through phosphorylation, and Akt subsequently phosphorylates a number of downstream targets, including m<sc>tor</sc> kinase, whose increasing phosphorylation by Akt further enhances protein synthesis. These Akt targets play key roles in regulating critical cellular functions including proliferation, apoptosis, glucose homeostasis, cell size, nutrient response, and <sc>dna</sc> damage <xref ref-type="bibr" rid="b6-co16-s1-s33">6</xref>&#x02013;<xref ref-type="bibr" rid="b8-co16-s1-s33">8</xref>.</p><p>In normal tissues, the tumour suppressor gene <italic>PTEN</italic> (phosphatase and tensin homologue deleted on chromosome 10) is a negative regulator of the Akt pathway, acting by downregulating <sc>pi</sc>3<sc>k</sc> hyperactivity through dephosphorylation of <sc>pip</sc>3 to <sc>pip</sc>2. In many cancers, this <italic>PTEN</italic> tumour suppressor function is not active, allowing <sc>pi</sc>3<sc>k</sc> to activate Akt. There is substantial evidence that inactivation of <italic>PTEN</italic> may be more important than mutation of <italic>p53</italic> in many adult epithelial tumours<xref ref-type="bibr" rid="b9-co16-s1-s33">9</xref>. Somatic alteration and mutation of <italic>PTEN</italic> has been shown to be a common event in tumours such as melanoma, glioblastoma, prostate cancer, and endometrial cancer <xref ref-type="bibr" rid="b10-co16-s1-s33">10</xref>.</p><p>The <sc>pten</sc> protein encoded by the <italic>PTEN</italic> gene is an enzyme that facilitates dephosphorylation of <sc>pip</sc>3 to <sc>pip</sc>2. With growth-factor stimulation (<sc>igf</sc>, <sc>egf</sc>, <sc>pdgf</sc>), <sc>pip</sc>3 is upregulated. Elevated <sc>pi</sc>3<sc>k</sc> has been linked to transformation by oncogenes and to stimulation through the <sc>pdgf</sc> receptor. The lipid phosphatase activity of <sc>pten</sc> and its ability to dephosphorylate <sc>pip</sc>3 and act as a &#x0201c;countermeasure&#x0201d; for <sc>pi</sc>3<sc>k</sc> signalling suggests that <sc>pten</sc> functions as a significant tumour suppressor by directly antagonizing the activity of the <sc>pi</sc>3<sc>k</sc>/Akt signalling pathway (<xref ref-type="fig" rid="f1-co16-s1-s33">Figure 1</xref>).</p><p>Significant research has now shown the tumour suppressor genes tuberous sclerosis 1 (<italic>TSC1</italic>) and 2 (<italic>TSC2</italic>) to be key inhibitors of the m<sc>tor</sc> pathway <xref ref-type="bibr" rid="b5-co16-s1-s33">5</xref>. After Akt is stimulated by growth factors and mitogenic stimuli through the <sc>pi</sc>3<sc>k</sc> pathway, the Akt complex phosphorylates and subsequently destabilizes the <sc>tsc</sc> complex (<xref ref-type="fig" rid="f2-co16-s1-s33">Figure 2</xref>). This destabilization of the tumor suppressors <sc>tsc</sc>1 and <sc>tsc</sc>2 subsequently activates m<sc>tor</sc> via a small protein called Rheb (<italic>ras</italic> homolog enriched in brain).</p></sec><sec><label>2.2</label><title>Dual Pathway Activity: Downstream mTOR Signalling Targets</title><p>The cell replication process is controlled by m<sc>tor</sc> through two downstream pathways (<xref ref-type="fig" rid="f3-co16-s1-s33">Figure 3</xref>) mediated by two key proteins: 4EBP1 (translation initiation factor 4E binding protein 1) and p70S6K1 (ribosomal p70S6 kinase). When 4EBP1 is activated by m<sc>tor</sc>, it dissociates from eIF-4E (eukaryotic translation factor), and leads to cap-dependent messenger (m<sc>rna</sc>) translation. These m<sc>rna</sc> encode for c-Myc, cyclin D1, ornithine decarboxylase, and hypoxia-inducible factor (<sc>hif</sc>), leading to upregulation of a number of growth factors, including the key angiogenic vascular endothelial growth factor (<sc>vegf</sc>), <sc>pdgf</sc>, and transforming growth factor (<sc>tgf</sc>) <xref ref-type="bibr" rid="b11-co16-s1-s33">11</xref>. Synthesis of <sc>hif</sc> is therefore partly regulated by m<sc>tor</sc> and normally degraded by the <italic>VHL</italic> (von Hippel&#x02013;Lindau) gene and its proteins. Dysregulation of the <italic>VHL</italic> gene, seen in clear-cell renal cell carcinomas, results in <sc>hif</sc>&#x003b1; overexpression and in increased <sc>vegf</sc>, <sc>pdgf</sc>, and <sc>tgf</sc>. Overexpression of <sc>hif</sc> can therefore be controlled by m<sc>tor</sc> inhibition. Activation of the p70S6K1 pathway leads to the translation of m<sc>rna</sc> that encodes ribosomal proteins, elongation factors, and other proteins that are necessary for movement from the G1 phase to the S phase of the cell cycle.</p><p>Substantial preclinical and clinical data have shown the <sc>pten</sc>/<sc>pi</sc>3<sc>k</sc>/Akt/m<sc>tor</sc> pathway to be a major oncogenic pathway in the development of some of the most common cancers and a major therapeutic target in the treatment of human malignancy.</p></sec></sec><sec><label>3.</label><title>INHIBITORS OF mTOR</title><sec><label>3.1</label><title>Sirolimus</title><p>Sirolimus (Rapamune: Wyeth, Madison, NJ, U.S.A.), initially discovered as an antifungal antibiotic from soil on Rapa Nui (formerly called Easter Island), was recognized in its early development to have anticancer activity (at high doses in murine models <xref ref-type="bibr" rid="b12-co16-s1-s33">12</xref>) and a significant immunosuppressive effect, which although detrimental in fighting infections, proved to be beneficial in transplantation <xref ref-type="bibr" rid="b13-co16-s1-s33">13</xref>. After its approval for transplant immunosuppression in 1999, sirolimus was found to have a significant antitumour effect in experimental models of <sc>rcc</sc>. <italic>In vitro</italic>, sirolimus changed murine renal cancer cells from an invasive to a noninvasive phenotype, reducing spread and metastatic progression. It also reduced cyclin D1 and increased p27<sup>Kip1</sup>, inhibiting G1-to-S transition <xref ref-type="bibr" rid="b14-co16-s1-s33">14</xref> and potentially slowing tumour growth <xref ref-type="bibr" rid="b15-co16-s1-s33">15</xref>.</p><p>In several murine models of <sc>rcc</sc> tumour progression, sirolimus was shown to slow tumour growth and metastatic progression and to prolong survival, even in the presence of pro-oncogenic cyclosporine <xref ref-type="bibr" rid="b14-co16-s1-s33">14</xref>. Further studies examining human <sc>rcc</sc> pulmonary metastases in mice with severe combined immunodeficiency demonstrated the antitumour efficacy of sirolimus with significant reduction of the pro-oncogenic cytokines <sc>tgf</sc>&#x003b2; and <sc>vegf</sc>
<xref ref-type="bibr" rid="b16-co16-s1-s33">16</xref>. In contrast to cyclosporine (which has been shown to promote <sc>tgf</sc>&#x003b2;), sirolimus has been shown to have an anti-angiogenic effect through downregulation of <sc>vegf</sc>
<xref ref-type="bibr" rid="b15-co16-s1-s33">15</xref> and potentially a specific effect on tumour vessel thrombosis, which may also contribute to its anti-neoplastic action through an indirect mechanism <xref ref-type="bibr" rid="b17-co16-s1-s33">17</xref>. Blockade of m<sc>tor</sc> has an inhibitory effect on activity by upstream molecules such as Akt, which occur in some cancers (for example, Kaposi sarcoma) because of loss of regulation by the tumor suppressor <sc>pten</sc>
<xref ref-type="bibr" rid="b9-co16-s1-s33">9</xref></p></sec><sec><label>3.2</label><title>Everolimus</title><p>Everolimus (RAD001: Novartis Pharmaceuticals, St. Louis, MO, U.S.A.) an oral m<sc>tor</sc> inhibitor, has been shown to have both immunosuppressant and anti-neoplastic properties. At the 2006 annual meeting of the American Society for Clinical Oncology (<sc>asco</sc>), Amato and colleagues presented a phase <sc>ii</sc> trial in patients with <sc>rcc</sc> treated with everolimus after cytokine or cytotoxic therapy. In that study, 25 patients receiving a daily dose of 10mg showed a median progression-free survival (<sc>pfs</sc>) of more than 9 months <xref ref-type="bibr" rid="b18-co16-s1-s33">18</xref>. In phase <sc>i</sc> and <sc>ii</sc> trials, the most common adverse events with everolimus were rash (46%), stomatitis or mucositis (40%), fatigue (32%), and nausea (25%). The most common laboratory abnormalities were anemia (9%), hypercholesterolemia (9%), hyperglycemia (8%), thrombocytopenia (7%), hypertriglyceridemia (3%), and leucopenia or neutropenia (2%).</p><p>These phase <sc>i</sc> and phase <sc>ii</sc> data in patients with advanced <sc>rcc</sc> identified significant activity that led to a subsequent larger phase <sc>iii</sc> second-line trial. In that trial <xref ref-type="bibr" rid="b19-co16-s1-s33">19</xref>, everolimus delayed disease progression in m<sc>rcc</sc> patients who had progressed on previous targeted therapy (sorafenib, sunitinib). The 410 study patients were randomized 2:1 (everolimus:placebo). The primary endpoint was <sc>pfs</sc>, with 290 events required to achieve 90% power. Secondary endpoints were safety, response, patient-reported outcomes, and <sc>os</sc>. Key eligibility criteria were m<sc>rcc</sc> with clear-cell component, measurable disease, and progressive disease at or within 6months of treatment with sunitinib, sorafenib, or both. (Prior bevacizumab and cytokine treatment were also permitted.) Crossover was allowed in the study, meaning that patients who progressed on therapy were unblinded and allowed to receive everolimus if they had been randomized to placebo.</p><p>Of the 410 patients randomized, 272 received everolimus 10mg daily, and 138 received placebo. Median age was 61 years in the treatment group and 60 years in the placebo group. main sites of metastasis were lung (73%, 81%), bone (37%, 31%), and liver (35%, 36%). more than 90% of the patients in both arms had more than one site of metastatic disease. Patients with prior nephrectomy constituted 96% of the everolimus arm and 95% of the placebo arm, and were otherwise comparable. In the everolimus arm, 46% of patients had been treated with sunitinib, 28% with sorafenib, and 28% with both agents. Patient discontinuation in the everolimus arm was 31% because of progressive disease, 10% because of adverse events, and 3% because of death. In the placebo arm, 73% patients discontinued because of progressive disease, 1% because of adverse events, and 2% because of death.</p><p>Interim analysis showed that median <sc>pfs</sc> was 4 months in the everolimus arm and 1.9 months in the control arm, a statistically significant difference (<italic>p</italic> &#x0003c; 0.001). Because of crossover, 80% patients on placebo switched to everolimus, and so <sc>os</sc> did not show a significant difference.</p><p>Inhibition of m<sc>tor</sc> with everolimus was fairly well tolerated. Common side effects were mouth ulcers or stomatitis (40% vs. 8% placebo), asthenia or fatigue (28% vs. 24%), rash (25% vs. 4%), diarrhea (17% vs. 3%), anorexia (16% vs. 6%), nausea (15% vs. 8%), vomiting (12% vs. 4%), cough (12% vs. 4%), peripheral edema (10% vs. 3%), pneumonitis (8% vs. 0%), and dyspnea (8% vs. 2%). Main laboratory abnormalities (all grades) included anemia (91% vs. 76%), lymphopenia (42% vs. 29%), thrombocytopenia (20% vs. 2%), and neutropenia (11% vs. 3%). Hypercholesterolemia, hypertriglyceridemia, and hyperglycemia were higher in the everolimus arm than in the placebo arm, as was expected, given the m<sc>tor</sc>-inhibitor class of the drug.</p><p>Based on these data showing statistically significant improvement in <sc>pfs</sc> as compared with placebo, everolimus established clinical benefit as a second-line therapy in patients who progress on first-line targeted therapy, including sunitinib and sorafenib. Everolimus can be proposed as the new standard of care in the second-line setting for patients progressing on targeted therapy with <sc>vegf</sc> inhibitor.</p></sec><sec><label>3.3</label><title>Temsirolimus</title><p>Temsirolimus, a soluble ester analog of rapamycin, was selected for development as an anticancer agent based on its prominent antitumour profile and favourable pharmacologic and toxicologic characteristics in preclinical studies <xref ref-type="bibr" rid="b20-co16-s1-s33">20</xref>. Compared with rapamycin, temsirolimus was found to have improved aqueous solubility, bioavailability, and stability as an anticancer agent <xref ref-type="bibr" rid="b21-co16-s1-s33">21</xref>.</p><p>Temsirolimus is a specific inhibitor of m<sc>tor</sc> kinase <xref ref-type="bibr" rid="b22-co16-s1-s33">22</xref> that binds to an intracellular protein, Fkbp12, which in turn forms a complex that inhibits the m<sc>tor</sc> pathway <xref ref-type="bibr" rid="b23-co16-s1-s33">23</xref>. By inhibiting m<sc>tor</sc> signalling, temsirolimus inhibits the translation of m<sc>rna</sc> that encodes proteins required for G1 progression and S-phase initiation, and that mediate cell growth and angiogenesis <xref ref-type="bibr" rid="b24-co16-s1-s33">24</xref>. In phase <sc>i</sc> studies, antitumour activity in a number of cancer types was observed over a broad dose range (<xref ref-type="table" rid="t1-co16-s1-s33">Table <sc>i</sc></xref>).</p><p>Although mutations in <italic>PTEN</italic> have not been detected, <italic>PTEN</italic> gene expression is often downregulated in <sc>rcc</sc>
<xref ref-type="bibr" rid="b29-co16-s1-s33">29</xref>. A phase <sc>ii</sc> single-agent study was conducted to evaluate the efficacy, safety, and pharmacokinetics of CCI-779 in patients with advanced refractory <sc>rcc</sc>. This randomized double-blind multicentre trial in 111 patients with cytokine-refractory m<sc>rcc</sc> included patients with poor-risk features. Patients were randomly assigned to receive 25 mg, 75 mg, or 250 mg CCI-779 weekly as a 30-minute intravenous (IV) infusion. Patients were evaluated for tumour response, time to tumour progression (<sc>ttp</sc>), survival, and adverse events. The CCI-779 produced an objective response rate of 7% (1 complete response and 7 partial responses) and minor responses in 26% of the study patients. Median <sc>ttp</sc> was 5.8 months, and median survival was 15.0 months (<xref ref-type="fig" rid="f4-co16-s1-s33">Figure 4</xref>). Within each risk group, the median survivals of patients at each dose level were similar.</p><p>The most frequently occurring adverse events of all grades related to CCI-779 were maculopapular rash (76%), mucositis (70%), asthenia (50%), and nausea (43%). Reasons for dose reductions included thrombocytopenia (20%), mucositis (16%), hypertriglyceridemia (5%), and neutropenia (1%). In 19% of patients, treatment was discontinued because of drug-related adverse events. Maculopapular rash (5 patients) was the most frequent reason for treatment discontinuation. Pneumonitis was seen in 6 patients, with 2 being withdrawn from study, 2 worsening after drug restart, and 2 having no recurrence of pneumonitis after drug restart. Retrospectively, 49 patients were categorized as being poor-prognosis patients. The CCI-779&#x02013;treated patients in this poor-risk group experienced a median <sc>os</sc> that was longer by a factor of 1.7 than that experienced by the first-line interferon-treated poor-risk group reported by Motzer <italic>et al.</italic>
<xref ref-type="bibr" rid="b30-co16-s1-s33">30</xref> (<xref ref-type="table" rid="t2-co16-s1-s33">Table <sc>ii</sc></xref>).</p><p>In a phase <sc>i</sc> study, the maximal tolerated dose of a combination of temsirolimus with interferon in advanced <sc>rcc</sc> patients was temsirolimus 15 mg IV once weekly with interferon 6&#x000d7;10<xref ref-type="bibr" rid="b6-co16-s1-s33">6</xref> IU subcutaneously 3 times weekly <xref ref-type="bibr" rid="b31-co16-s1-s33">31</xref>. The significant activity noted in patients with poor-prognosis features led to a major phase <sc>iii</sc> trial in advanced <sc>rcc</sc> patients with poor prognostic features. Patients with advanced <sc>rcc</sc> and no prior systemic therapy were enrolled in the open-label study if they had at least 3 of the following 6 Mekhail poor-prognosis risk factors:
<list list-type="bullet"><list-item><p>Lactate dehydrogenase level greater than 1.5 times the upper limit of normal</p></list-item><list-item><p>Hemoglobin below the lower limit of normal</p></list-item><list-item><p>Corrected calcium greater than 10 mg/dL</p></list-item><list-item><p>Time from diagnosis to first treatment under 1 year</p></list-item><list-item><p>Karnofsky performance status 60&#x02013;70</p></list-item><list-item><p>Disease metastatic to multiple organs</p></list-item></list></p><p>At 209 sites in 26 countries, 626 patients were enrolled, of whom 67% had undergone prior nephrectomy. That proportion of patients with nephrectomy was much lower than the more than 90% of patients with prior nephrectomy in the sunitinib and sorafenib registration trials, likely because the temsirolimus&#x02013;interferon patients had a poor prognosis and may not have been able to tolerate surgical intervention.</p><p>Patients were randomized (1:1:1) to one of 3 arms:
<list list-type="bullet"><list-item><p>interferon up to 18&#x000d7;10<xref ref-type="bibr" rid="b6-co16-s1-s33">6</xref> IU subcutaneously 3 times weekly (arm 1),</p></list-item><list-item><p>temsirolimus 25 mg IV once weekly (arm 2), or</p></list-item><list-item><p>temsirolimus 15 mg IV once weekly with interferon 6&#x000d7;10<xref ref-type="bibr" rid="b6-co16-s1-s33">6</xref> IU subcutaneously 3 times weekly (arm 3).</p></list-item></list></p><p>The primary study endpoint was <sc>os</sc>, and the study was powered to compare the temsirolimus arms with the interferon-only arm.</p><p>The three most frequently occurring adverse events were asthenia (27% in arm 1, 12% in arm 2, 30% in arm 3), anemia (24%, 21%, 39%), and dyspnea (8%, 9%, 11%). Less-common adverse events included nausea (5%, 4%, 2%), vomiting (0%, 1%, 5%), hyperlipidemia (1%, 7%, 2%), hyperglycemia (1%, 10%, 4%), thrombocytopenia (0%, 1%, 9%), and neutropenia (8%, 3%, 14%). The proportion of patients with any grade 3 or 4 adverse event was 85% in arm 1, 69% in arm 2, and 87% in arm 2, with the difference between temsirolimus and interferon and between temsirolimus and temsirolimus&#x02013;interferon being statistically significant (<italic>p</italic> &#x02264; 0.001). More patients in the interferon groups discontinued treatment because of adverse events (14, 7, and 22 patients respectively).</p><p>As compared with interferon alfa (<italic>n</italic> = 207), single-agent temsirolimus (<italic>n</italic> = 209) was observed to significantly increase <sc>os</sc> (10.9 months vs. 7.3 months, <italic>p</italic> = 0.0069) in patients with m<sc>rcc</sc> judged to be poor-risk. By treatment arm, <sc>os</sc> was 7.3 months (interferon), 10.9 months (temsirolimus), and 8.4 months (temsirolimus&#x02013;interferon). Median <sc>pfs</sc> (<xref ref-type="fig" rid="f5-co16-s1-s33">Figure 5</xref>) was 1.9 months, 3.7 months, and 3.7 months, and objective response (complete and partial responses together) was 7%, 9%, and 11% respectively. The conclusion from the study was that, compared with interferon, single-agent temsirolimus (25 mg IV weekly) significantly increases <sc>os</sc>, with an acceptable safety profile, in first-line poor-risk advanced <sc>rcc</sc> patients <xref ref-type="bibr" rid="b3-co16-s1-s33">3</xref>. This study was the first to show a statistically significant benefit in <sc>os</sc> as well as in <sc>pfs</sc> with targeted therapy in m<sc>rcc</sc> patients with poor-prognosis features. It led to approvals by Health Canada and the U.S. Food and Drug Administration of temsirolimus for the first-line treatment of poor-prognosis patients with advanced <sc>rcc</sc>.</p></sec></sec><sec sec-type="conclusions"><label>4.</label><title>CONCLUSIONS</title><p>The importance of m<sc>tor</sc> as a novel target in the treatment of advanced <sc>rcc</sc> has been demonstrated in phase <sc>iii</sc> clinical trials, both for first-line and second-line treatment after failure of <sc>vegfr</sc>-<sc>rtk</sc> inhibitors. The m<sc>tor</sc> inhibitors temsirolimus and everolimus are well tolerated by patients with advanced <sc>rcc</sc>. The m<sc>tor</sc> inhibitors continue to be investigated as single agents and in combination with other anti-neoplastic agents such as <sc>rtk</sc> inhibitors and <sc>vegf</sc> inhibitors in <sc>rcc</sc> and other malignancies.</p></sec></body><back><ref-list><title>5. REFERENCES</title><ref id="b1-co16-s1-s33"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><etal/></person-group><article-title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>115</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">17215529</pub-id></element-citation></ref><ref id="b2-co16-s1-s33"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><etal/><collab>on behalf of the <sc>target</sc> Study Group</collab></person-group><article-title>Sorafenib in advanced clear-cell renal-cell carcinoma</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>125</fpage><lpage>34</lpage><comment>[Erratum in: N Engl J Med 2007;357:203]</comment><pub-id pub-id-type="pmid">17215530</pub-id></element-citation></ref><ref id="b3-co16-s1-s33"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudes</surname><given-names>G</given-names></name><name><surname>Carducci</surname><given-names>M</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><etal/><collab>on behalf of the Global <sc>arcc</sc> Trial</collab></person-group><article-title>Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>2271</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">17538086</pub-id></element-citation></ref><ref id="b4-co16-s1-s33"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornsti</surname><given-names>MA</given-names></name><name><surname>Houghton</surname><given-names>PJ</given-names></name></person-group><article-title>The <sc>tor</sc> pathway: a target for cancer therapy</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>335</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">15122205</pub-id></element-citation></ref><ref id="b5-co16-s1-s33"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adjei</surname><given-names>AA</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name></person-group><article-title>Intracellular signal transduction pathway proteins as targets for cancer therapy</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>5386</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">15983388</pub-id></element-citation></ref><ref id="b6-co16-s1-s33"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacinto</surname><given-names>E</given-names></name><name><surname>Loewith</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mammalian <sc>tor</sc> complex 2 controls the actin cytoskeleton and is rapamycin insensitive</article-title><source>Nat Cell Biol</source><year>2004</year><volume>6</volume><fpage>1122</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15467718</pub-id></element-citation></ref><ref id="b7-co16-s1-s33"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hresko</surname><given-names>RC</given-names></name><name><surname>Mueckler</surname><given-names>M</given-names></name></person-group><article-title><sc>mtor.rictor</sc> is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>40406</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">16221682</pub-id></element-citation></ref><ref id="b8-co16-s1-s33"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarbassov</surname><given-names>DD</given-names></name><name><surname>Guertin</surname><given-names>DA</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><article-title>Phosphorylation and regulation of Akt/<sc>pkb</sc> by the <sc>rictor</sc>-m<sc>tor</sc> complex</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>1098</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">15718470</pub-id></element-citation></ref><ref id="b9-co16-s1-s33"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yen</surname><given-names>C</given-names></name><name><surname>Liaw</surname><given-names>D</given-names></name><etal/></person-group><article-title><italic>PTEN</italic> a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>1943</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9072974</pub-id></element-citation></ref><ref id="b10-co16-s1-s33"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansal</surname><given-names>I</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name></person-group><article-title>The biology and clinical relevance of the <sc>pten</sc> tumor suppressor pathway</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>2954</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15254063</pub-id></element-citation></ref><ref id="b11-co16-s1-s33"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houghton</surname><given-names>PJ</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name></person-group><article-title>m<sc>tor</sc> as a target for cancer therapy</article-title><source>Curr Top Microbiol Immunol</source><year>2004</year><volume>279</volume><fpage>339</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">14560967</pub-id></element-citation></ref><ref id="b12-co16-s1-s33"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>CP</given-names></name><name><surname>Sehgal</surname><given-names>SN</given-names></name><name><surname>V&#x000e9;zina</surname><given-names>C</given-names></name></person-group><article-title>Activity of rapamycin (AY-22,989) against transplanted tumors</article-title><source>J Antibiot (Tokyo)</source><year>1984</year><volume>37</volume><fpage>1231</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">6501094</pub-id></element-citation></ref><ref id="b13-co16-s1-s33"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehgal</surname><given-names>SN</given-names></name></person-group><article-title>Rapamune (<sc>rapa</sc>, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression</article-title><source>Clin Biochem</source><year>1998</year><volume>31</volume><fpage>335</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">9721431</pub-id></element-citation></ref><ref id="b14-co16-s1-s33"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>FL</given-names></name><name><surname>Hojo</surname><given-names>M</given-names></name><name><surname>Maluccio</surname><given-names>M</given-names></name><name><surname>Yamaji</surname><given-names>K</given-names></name><name><surname>Suthanthiran</surname><given-names>M</given-names></name></person-group><article-title>Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy</article-title><source>Transplantation</source><year>2002</year><volume>73</volume><fpage>1565</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">12042641</pub-id></element-citation></ref><ref id="b15-co16-s1-s33"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nourse</surname><given-names>J</given-names></name><name><surname>Firpo</surname><given-names>E</given-names></name><name><surname>Flanagan</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Interleukin-2&#x02013;mediated elimination of the p27<sup>Kip1</sup> cyclin-dependent kinase inhibitor prevented by rapamycin</article-title><source>Nature</source><year>1994</year><volume>372</volume><fpage>570</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7990932</pub-id></element-citation></ref><ref id="b16-co16-s1-s33"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>FL</given-names></name><name><surname>Ding</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>VK</given-names></name><name><surname>Chon</surname><given-names>WJ</given-names></name><name><surname>Lagman</surname><given-names>M</given-names></name><name><surname>Suthanthiran</surname><given-names>M</given-names></name></person-group><article-title>Rapamycin is an effective inhibitor of human renal cancer metastasis</article-title><source>Kidney Int</source><year>2003</year><volume>63</volume><fpage>917</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">12631072</pub-id></element-citation></ref><ref id="b17-co16-s1-s33"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guba</surname><given-names>M</given-names></name><name><surname>von Breitenbuch</surname><given-names>P</given-names></name><name><surname>Steinbauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>128</fpage><lpage>35</lpage><comment>[See comment]</comment><pub-id pub-id-type="pmid">11821896</pub-id></element-citation></ref><ref id="b18-co16-s1-s33"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>RJ</given-names></name><name><surname>Jac</surname><given-names>J</given-names></name></person-group><article-title>Targeted anti-cancer therapies for renal cancer</article-title><source>Drugs</source><year>2006</year><volume>66</volume><fpage>2161</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17137401</pub-id></element-citation></ref><ref id="b19-co16-s1-s33"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><etal/><collab>on behalf of the <sc>record</sc>-1 Study Group</collab></person-group><article-title>Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase <sc>iii</sc> trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>449</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">18653228</pub-id></element-citation></ref><ref id="b20-co16-s1-s33"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Toral&#x02013;Barza</surname><given-names>L</given-names></name><name><surname>Discafani</surname><given-names>C</given-names></name><etal/></person-group><article-title>m<sc>tor</sc>, a novel target in breast cancer: the effect of CCI-779, an m<sc>tor</sc> inhibitor, in preclinical models of breast cancer</article-title><source>Endocr Relat Cancer</source><year>2001</year><volume>8</volume><fpage>249</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">11566616</pub-id></element-citation></ref><ref id="b21-co16-s1-s33"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>E</given-names></name><name><surname>Alexandre</surname><given-names>J</given-names></name><name><surname>Faivre</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel m<sc>tor</sc> inhibitor, in patients with cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>2336</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15136596</pub-id></element-citation></ref><ref id="b22-co16-s1-s33"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmelzle</surname><given-names>T</given-names></name><name><surname>Hall</surname><given-names>MN</given-names></name></person-group><article-title><sc>tor</sc>, a central controller of cell growth</article-title><source>Cell</source><year>2000</year><volume>103</volume><fpage>253</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">11057898</pub-id></element-citation></ref><ref id="b23-co16-s1-s33"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skotnicki</surname><given-names>JS</given-names></name><name><surname>Leone</surname><given-names>CL</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779 [abstract 477]</article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><issue>suppl</issue><fpage>3749S</fpage><lpage>50S</lpage></element-citation></ref><ref id="b24-co16-s1-s33"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>GV</given-names></name><name><surname>Tran</surname><given-names>C</given-names></name><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><etal/></person-group><article-title>Hypoxia-inducible factor determines sensitivity to inhibitors of m<sc>tor</sc> in kidney cancer</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>122</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16341243</pub-id></element-citation></ref><ref id="b25-co16-s1-s33"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidalgo</surname><given-names>M</given-names></name><name><surname>Rowinsky</surname><given-names>EK</given-names></name></person-group><article-title>The rapamycin-sensitive signal transduction pathway as a target for cancer therapy</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>6680</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11426655</pub-id></element-citation></ref><ref id="b26-co16-s1-s33"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forouzesh</surname><given-names>B</given-names></name><name><surname>Buckner</surname><given-names>J</given-names></name><name><surname>Adjei</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase 1, bioavailability, and pharmacokinetic study of the oral dosage of CCI-779 administered to patients with advanced solid malignancies [abstract 168]</article-title><source>Eur J Cancer</source><year>2002</year><volume>38</volume><issue>suppl 7</issue><fpage>54</fpage></element-citation></ref><ref id="b27-co16-s1-s33"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punt</surname><given-names>CJ</given-names></name><name><surname>Boni</surname><given-names>J</given-names></name><name><surname>Bruntsch</surname><given-names>U</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Thielert</surname><given-names>C</given-names></name></person-group><article-title>Phase <sc>i</sc> and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><fpage>931</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12796032</pub-id></element-citation></ref><ref id="b28-co16-s1-s33"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>SM</given-names></name><name><surname>Kuhn</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>P</given-names></name><etal/><collab>on behalf of the North American Brain Tumor Consortium and the National Cancer Institute</collab></person-group><article-title>Phase <sc>i</sc>/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs</article-title><source>Invest New Drugs</source><year>2004</year><volume>22</volume><fpage>427</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">15292713</pub-id></element-citation></ref><ref id="b29-co16-s1-s33"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Randomized phase <sc>ii</sc> study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>909</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">14990647</pub-id></element-citation></ref><ref id="b30-co16-s1-s33"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Bacik</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>BA</given-names></name><name><surname>Russo</surname><given-names>P</given-names></name><name><surname>Mazumdar</surname><given-names>M</given-names></name></person-group><article-title>Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>289</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11773181</pub-id></element-citation></ref><ref id="b31-co16-s1-s33"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JW</given-names></name><name><surname>Ko</surname><given-names>YJ</given-names></name><name><surname>Dutcher</surname><given-names>J</given-names></name><etal/></person-group><article-title>Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-&#x003b1; to patients with advanced renal cell carcinoma</article-title><source>Proc Am Soc Clin Oncol</source><year>2004</year><volume>22</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=26&#x00026;abstractID=433">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=26&#x00026;abstractID=433</ext-link>; cited March 22, 2009]</comment></element-citation></ref></ref-list></back><floats-group><fig id="f1-co16-s1-s33" position="float"><label>FIGURE 1</label><caption><p>The phosphoinositide 3 kinase (pi3k)/protein kinase B (Akt) signalling pathway <xref ref-type="bibr" rid="b10-co16-s1-s33">10</xref>. pip2 = phosphatidylinositol (4,5)-bisphosphate; pip3 = phosphatidylinositol (3,4,5)-trisphosphate; pten = phosphatase and tensin homolog.</p></caption><graphic xlink:href="co16-s1-s33f1"/></fig><fig id="f2-co16-s1-s33" position="float"><label>FIGURE 2</label><caption><p>Stimulation of protein kinase B (Akt) by growth factors and mitogens in a pi3k (phosphoinositide 3 kinase)&#x02013;dependent manner phosphorylates and subsequently destabilizes the tuberous sclerosis (Tsc1/Tsc2) complex. <xref ref-type="bibr" rid="b10-co16-s1-s33">10</xref> pdk = pyruvate dehydrogenase kinase; mtor = mammalian target of rapamycin.</p></caption><graphic xlink:href="co16-s1-s33f2"/></fig><fig id="f3-co16-s1-s33" position="float"><label>FIGURE 3</label><caption><p>Control of the cell replication process by mammalian target of rapamycin (mtor) through two downstream pathways <xref ref-type="bibr" rid="b10-co16-s1-s33">10</xref>. 4EBP1/eIF-4E = eukaryotic translation initiation factor 4E binding protein 1 / eukaryotic translation factor; p70S6K = ribosomal p70S6 kinase.</p></caption><graphic xlink:href="co16-s1-s33f3"/></fig><fig id="f4-co16-s1-s33" position="float"><label>FIGURE 4</label><caption><p>Median time to tumour progression in patients randomly assigned to receive 25 mg, 75 mg, or 250 mg of CCI-779 (temsirolimus) weekly <xref ref-type="bibr" rid="b29-co16-s1-s33">29</xref>.</p></caption><graphic xlink:href="co16-s1-s33f4"/></fig><fig id="f5-co16-s1-s33" position="float"><label>FIGURE 5</label><caption><p>Plot of overall survival, the primary study endpoint in a comparison of temsirolimus and interferon as single agents and in combination <xref ref-type="bibr" rid="b3-co16-s1-s33">3</xref>.</p></caption><graphic xlink:href="co16-s1-s33f5"/></fig><table-wrap id="t1-co16-s1-s33" position="float"><label>TABLE I</label><caption><p>Phase i clinical trials with temsirolimus <xref ref-type="bibr" rid="b5-co16-s1-s33">5</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1"><italic>Reference</italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>Tumour type</italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>Pts</italic>
<italic><sc>(</sc></italic><sc>n</sc><italic><sc>)</sc></italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>Daily dose</italic>
<italic><sc>(mg)</sc></italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>Regimen</italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>Daily</italic>
<italic><sc>mtd (mg)</sc></italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>Toxicity</italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>Activity</italic></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Hidalgo <italic>et al.,</italic> 2000<xref ref-type="bibr" rid="b25-co16-s1-s33">25</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Renal cell carcinoma, <sc>nsclc</sc>, soft-tissue sarcomas, cervical and uterine carcinomas</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">0.75&#x02013;19.1/m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1">Intravenous days 1&#x02013;5 every 2 weeks</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02014;<xref ref-type="table-fn" rid="tfn1-co16-s1-s33">a</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Hypocalcemia, skin rash, stomatitis, thrombocytopenia</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>pr</sc>: 2%
<break/><sc>mr</sc> or <sc>sd</sc>: 15%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Farouzesh <italic>et al.,</italic> 2002<xref ref-type="bibr" rid="b26-co16-s1-s33">26</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Renal cell carcinoma, <sc>nsclc</sc>, myxoid chondrosarcoma, mesothelioma, leyomiosarcoma</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">25&#x02013;75</td><td valign="top" align="center" rowspan="1" colspan="1">Oral, days 1&#x02013;5 every 2 weeks</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">Stomatitis, rash, hypertransaminemia</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>sd</sc>: 33%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Punt <italic>et al.,</italic> 2003<xref ref-type="bibr" rid="b27-co16-s1-s33">27</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Colorectal, gastric carcinoma, esophageal, head-and-neck cancer</td><td valign="top" align="center" rowspan="1" colspan="1">28</td><td valign="top" align="center" rowspan="1" colspan="1">15&#x02013;75/m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1">Temsirolimus in combination with 5-<sc>fu/lv</sc></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02014;</td><td valign="top" align="center" rowspan="1" colspan="1">Stomatitis/mucositis</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>pr</sc> : 11%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Raymond <italic>et al.,</italic> 2004<xref ref-type="bibr" rid="b21-co16-s1-s33">21</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Renal cell carcinoma, soft-tissue sarcoma, mesothelioma, <sc>nsclc</sc>, breast, head-and-neck, melanoma, pancreatic, prostate, neuroendocrine, adrenocortical carcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">7.5&#x02013;220/m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1">Intravenous weekly</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02014;</td><td valign="top" align="center" rowspan="1" colspan="1">Skin rash, stomatitis, thrombocytopenia, bipolar disorder</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>pr</sc> : 8.3%
<break/><sc>mr</sc>: 8%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chang <italic>et al.,</italic> 2004<xref ref-type="bibr" rid="b28-co16-s1-s33">28</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Glioblastoma</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">250&#x02013;300</td><td valign="top" align="center" rowspan="1" colspan="1">Temsirolimus in combination with enzyme-inducing anti-epileptic drugs, weekly</td><td valign="top" align="center" rowspan="1" colspan="1">250</td><td valign="top" align="center" rowspan="1" colspan="1">Stomatitis, hypertriglyceridemia</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-co16-s1-s33"><p><sup>a</sup> 15 mg/m<sup>2</sup> in heavily pretreated patients.</p></fn><fn id="tfn2-co16-s1-s33"><p>Pts = patients; <sc>mtd</sc> = maximal tolerated dose; <sc>nsclc</sc> = non-small-cell lung cancer; <sc>pr</sc> = partial response; <sc>mr</sc> = minor response; <sc>sd</sc> = stable disease; 5-<sc>fu</sc> = 5-fluorouracil; <sc>lv</sc> =leucovorin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-co16-s1-s33" position="float"><label>TABLE II</label><caption><p>Median survival of renal cell carcinoma patients treated with temsirolimus, by risk group <xref ref-type="bibr" rid="b29-co16-s1-s33">29</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="left" rowspan="3" colspan="1"><italic>Dose level (mg)</italic></th><th valign="bottom" align="center" rowspan="3" colspan="1"><italic>Pts (</italic>n<italic>)</italic></th><th valign="bottom" align="center" colspan="4" rowspan="1"><italic>Good</italic></th><th valign="bottom" align="center" colspan="4" rowspan="1"><italic>Intermediate</italic></th><th valign="bottom" align="center" colspan="4" rowspan="1"><italic>Poor</italic></th></tr><tr><th valign="bottom" align="center" colspan="2" rowspan="1"><italic>Pts</italic></th><th valign="bottom" align="center" colspan="2" rowspan="1"><italic>Survival (months)</italic></th><th valign="bottom" align="center" colspan="2" rowspan="1"><italic>Pts</italic></th><th valign="bottom" align="center" colspan="2" rowspan="1"><italic>Survival (months)</italic></th><th valign="bottom" align="center" colspan="2" rowspan="1"><italic>Pts</italic></th><th valign="bottom" align="center" colspan="2" rowspan="1"><italic>Survival (months)</italic></th></tr><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>(</italic>n<italic>)</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>(%)</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>Median</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>95%</italic>
<italic><sc>ci</sc></italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>(</italic>n<italic>)</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>(%)</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>Median</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>95% Ci</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>(</italic>n<italic>)</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>(%)</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>Median</italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>95%</italic>
<italic><sc>ci</sc></italic></th></tr></thead><tbody><tr><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">36</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">18.4</td><td valign="top" align="center" rowspan="1" colspan="1">18.4 to 23.6</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">39</td><td valign="top" align="center" rowspan="1" colspan="1">23.0</td><td valign="top" align="center" rowspan="1" colspan="1">12.5 to <sc>na</sc></td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">56</td><td valign="top" align="center" rowspan="1" colspan="1">7.1</td><td valign="top" align="center" rowspan="1" colspan="1">4.1 to 15.0</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">75</td><td valign="top" align="center" rowspan="1" colspan="1">35<xref ref-type="table-fn" rid="tfn3-co16-s1-s33">a</xref></td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>na</sc></td><td valign="top" align="center" rowspan="1" colspan="1">24.1 to <sc>na</sc></td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">40</td><td valign="top" align="center" rowspan="1" colspan="1">20.9</td><td valign="top" align="center" rowspan="1" colspan="1">10.4 to 26.1</td><td valign="top" align="center" rowspan="1" colspan="1">19</td><td valign="top" align="center" rowspan="1" colspan="1">54</td><td valign="top" align="center" rowspan="1" colspan="1">8.6</td><td valign="top" align="center" rowspan="1" colspan="1">7.3 to 10.3</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">250</td><td valign="top" align="center" rowspan="1" colspan="1">34<xref ref-type="table-fn" rid="tfn3-co16-s1-s33">a</xref></td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">22.4</td><td valign="top" align="center" rowspan="1" colspan="1">14.4 to <sc>na</sc></td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">59</td><td valign="top" align="center" rowspan="1" colspan="1">19.3</td><td valign="top" align="center" rowspan="1" colspan="1">16.5 to 29.5</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">8.4</td><td valign="top" align="center" rowspan="1" colspan="1">3.9 to 17.3</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">All</td><td valign="top" align="center" rowspan="1" colspan="1">105</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">23.8</td><td valign="top" align="center" rowspan="1" colspan="1">17.7 to 27.1</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">46</td><td valign="top" align="center" rowspan="1" colspan="1">22.5</td><td valign="top" align="center" rowspan="1" colspan="1">16.9 to 25.7</td><td valign="top" align="center" rowspan="1" colspan="1">49</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">8.2</td><td valign="top" align="center" rowspan="1" colspan="1">7.0 to 10.1</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-co16-s1-s33"><p><sup>a</sup> For 3 patients, data for 1 or more of the prognostic factors were missing. These patients could not be assigned to a risk group.</p></fn><fn id="tfn4-co16-s1-s33"><p>Pts = patients; <sc>ci</sc> = confidence interval; <sc>na</sc> = not available.</p></fn></table-wrap-foot></table-wrap></floats-group></article>